Enovis (ENOV) | Financial Analysis & Statements
Enovis Corporation Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
575.8M
Gross Profit
349.4M
60.69%
Operating Income
48.3M
8.38%
Net Income
-520.5M
-90.39%
EPS (Diluted)
$-9.10
Balance Sheet Metrics
Total Assets
3.8B
Total Liabilities
2.3B
Shareholders Equity
1.5B
Debt to Equity
1.57
Cash Flow Metrics
Operating Cash Flow
-414.9M
Free Cash Flow
32.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Enovis Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.2B | 2.1B | 1.7B | 1.6B | 1.4B |
| Cost of Goods Sold | 902.8M | 926.9M | 716.4M | 693.7M | 648.5M |
| Gross Profit | 1.3B | 1.2B | 990.8M | 869.4M | 777.7M |
| Gross Margin % | 59.8% | 56.0% | 58.0% | 55.6% | 54.5% |
| Operating Expenses | |||||
| Research & Development | 120.3M | 91.3M | 75.3M | 60.8M | 49.1M |
| Selling, General & Administrative | 1.1B | 1.0B | 830.3M | 772.9M | 665.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.2B | 1.1B | 905.6M | 833.7M | 714.9M |
| Operating Income | -18.9M | -103.4M | -48.4M | -90.7M | -54.1M |
| Operating Margin % | -0.8% | -4.9% | -2.8% | -5.8% | -3.8% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 34.8M | 57.1M | 19.7M | 24.1M | 29.1M |
| Other Non-Operating Income | -1.1B | -662.4M | 995.0K | 112.6M | -38.6M |
| Pre-tax Income | -1.2B | -822.9M | -67.1M | -2.1M | -121.8M |
| Income Tax | 22.3M | 4.5M | -13.3M | 36.1M | -19.5M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -1.2B | -824.8M | -32.7M | -11.8M | 76.3M |
| Net Margin % | -52.7% | -39.1% | -1.9% | -0.8% | 5.3% |
| Key Metrics | |||||
| EBITDA | 275.1M | 191.3M | 194.4M | 131.1M | 208.8M |
| EPS (Basic) | $-20.75 | $-14.93 | $-0.61 | $-0.25 | $1.41 |
| EPS (Diluted) | $-20.75 | $-14.93 | $-0.61 | $-0.25 | $1.38 |
| Basic Shares Outstanding | 57068626 | 55290958 | 54526230 | 53168000 | 50820517 |
| Diluted Shares Outstanding | 57068626 | 55290958 | 54526230 | 53168000 | 50820517 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Enovis Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 36.4M | 48.2M | 36.2M | 24.3M | 680.3M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 442.8M | 407.0M | 291.5M | 267.4M | 255.0M |
| Inventory | 584.4M | 547.1M | 468.8M | 426.6M | 356.2M |
| Other Current Assets | 101.2M | 107.9M | 71.1M | 48.2M | 29.2M |
| Total Current Assets | 1.2B | 1.1B | 896.5M | 795.0M | 2.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 72.3M | 68.9M | 63.5M | 66.9M | 76.5M |
| Goodwill | 2.7B | 4.7B | 5.2B | 5.1B | 5.0B |
| Intangible Assets | 1.2B | 1.3B | 1.1B | 1.1B | 1.2B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 93.3M | 88.8M | 90.3M | 80.3M | 2.8B |
| Total Non-Current Assets | 2.6B | 3.6B | 3.6B | 3.5B | 6.2B |
| Total Assets | 3.8B | 4.7B | 4.5B | 4.3B | 8.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 187.5M | 179.1M | 132.5M | 135.6M | 155.2M |
| Short-term Debt | 59.7M | 42.4M | 21.6M | 243.6M | 29.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 51.5M | 3.6M | - | - | 635.3M |
| Total Current Liabilities | 598.5M | 529.0M | 369.6M | 565.2M | 1.0B |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.3B | 1.4B | 514.8M | 91.3M | 2.1B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 424.6M | 263.5M | 204.2M | 167.0M | 122.2M |
| Total Non-Current Liabilities | 1.7B | 1.6B | 719.0M | 258.2M | 2.8B |
| Total Liabilities | 2.3B | 2.2B | 1.1B | 823.4M | 3.9B |
| Equity | |||||
| Common Stock | 57.0K | 56.0K | 55.0K | 54.0K | 52.0K |
| Retained Earnings | -1.5B | -283.0M | 542.5M | 575.7M | 589.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.5B | 2.6B | 3.4B | 3.4B | 4.7B |
| Key Metrics | |||||
| Total Debt | 1.4B | 1.4B | 536.4M | 334.8M | 2.2B |
| Working Capital | 608.6M | 617.4M | 526.9M | 229.8M | 1.3B |
Balance Sheet Composition
Enovis Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -1.2B | -824.8M | -32.7M | -11.8M | 76.3M |
| Depreciation & Amortization | 294.4M | 284.8M | 217.1M | 219.7M | 262.9M |
| Stock-Based Compensation | 32.9M | 29.7M | 34.1M | 39.0M | 35.4M |
| Working Capital Changes | 15.5M | -13.9M | -27.3M | -222.3M | -17.1M |
| Operating Cash Flow | -835.7M | -529.0M | 166.5M | 34.9M | 340.0M |
| Investing Activities | |||||
| Capital Expenditures | -197.4M | -180.7M | -89.7M | -102.7M | -97.2M |
| Acquisitions | 16.4M | -769.9M | -152.8M | -73.7M | -223.3M |
| Investment Purchases | - | -4.8M | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -181.0M | -955.5M | -242.5M | -176.4M | -320.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 544.0M | 1.4B | 915.0M | 515.0M | 991.5M |
| Debt Repayment | -580.9M | -532.8M | -697.8M | -2.1B | -1.1B |
| Financing Cash Flow | -52.4M | 846.8M | -115.0M | -1.4B | 1.2B |
| Free Cash Flow | 19.9M | -67.2M | 12.8M | -161.3M | 251.9M |
| Net Change in Cash | -1.1B | -637.7M | -191.0M | -1.5B | 1.2B |
Cash Flow Trend
Enovis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.10
Forward P/E
5.94
Price to Book
0.91
Price to Sales
0.61
PEG Ratio
0.04
Profitability Ratios
Profit Margin
-52.69%
Operating Margin
6.09%
Return on Equity
-58.27%
Return on Assets
1.09%
Financial Health
Current Ratio
2.02
Debt to Equity
92.47
Beta
1.59
Per Share Data
EPS (TTM)
$-20.72
Book Value per Share
$26.05
Revenue per Share
$39.39
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ENOV | 1.3B | -1.10 | 0.91 | -58.27% | -52.69% | 92.47 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






